Meningitis News and Research

Latest Meningitis News and Research

CREW calls for antitrust investigation into drug companies

Today, Citizens for Responsibility and Ethics in Washington (CREW) sent a letter to the Federal Trade Commission (FTC) asking for an antitrust investigation into drug companies that offer significant discounts to doctors for providing patients with only that company's vaccines. CREW sent its letter after learning that Sanofi Pasteur and Merck require physician healthcare groups purchasing their vaccines to enter into contracts prohibiting them from purchasing vaccines made by other companies.

7 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

AP reports on how newly approved meningitis vaccine could 'revolutionalize' prevention of disease in Africa

The WHO's recent prequalification approval of a low-cost meningitis vaccine could "help prevent epidemics in Africa for the first time, revolutionizing how doctors fight outbreaks of the deadly disease," the Associated Press reports.

2 Jul 2010

ESMT CA study: Cutting pharmaceutical prices will reduce number of new medications

Cutting pharmaceutical prices will severely reduce the number of new medications making it to market, according to a groundbreaking independent study from ESMT Competition Analysis. For the first time, the study on 'Pharmaceutical Innovation and Pricing Regulation' clearly models and quantifies the direct link between strict regulation and low innovation.

1 Jul 2010

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.

1 Jul 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Health Canada recommends new pneumococcal vaccine for young children

In December, 2009, Health Canada approved a new vaccine for children aged six weeks through five years to prevent infections caused by the bacteria called pneumococcus or Streptococcus.

29 Jun 2010

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests.

28 Jun 2010

Scientist at Children Hospital Los Angeles receives NIH grant to research on meningitis

A white blood cell that normally removes bacteria from the bloodstream helps Escherichia coli (E. coli) accumulate in the blood and enter the brain resulting in the deadly infection known as meningitis. Prasadarao V. Nemani, PhD, a scientist at The Saban Research Institute at Children Hospital Los Angeles plans to find out how this happens with a grant of $1.65 million from the National Institutes of Health - National Institute of Neurological Disorders and Strokes.

25 Jun 2010

Researchers say ear tubes are safe for children with cochlear implants

Children who are being treated for hearing loss with cochlear implants can safely have ear tubes installed to help clear up infections, say researchers at the University of Alabama at Birmingham (UAB).

25 Jun 2010

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

This bacterium, Escherichia coli K1, is the most common cause of meningitis in premature infants and the second most common cause of the disease in newborns. "The ineffectiveness of antibiotics in treating newborns with meningitis and the emergence of antibiotic-resistant strains of bacteria require new strategies," explains Nemani V. Prasadarao, PhD, associate professor of infectious disease at Childrens Hospital Los Angeles.

17 Jun 2010

sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

As a longstanding partner in Canada's public health system, sanofi pasteur congratulates the Canadian Public Health Association (CPHA) for their 100 years of leadership and service to our country's public health.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

8 Jun 2010

BGS develops new bio filters for testing E. coli, salmonella, listeria and pseudomonas in food samples

BioSpec Global Solutions Inc., and partner -ICBS Ltd., announced today that it has begun development of three new bio filter for the testing of E. coli, salmonella, listeria and pseudomonas in food samples. Development of the Antibody/antigen multiple discrete filters and optical system for the simultaneous analysis of E.coli, salmonella, listeria and pseudomonas in food samples.

7 Jun 2010

Natural anti-inflammatory protein effective against meningitis-causing bacteria

A study published online on May 24th in the Journal of Experimental Medicine (www.jem.org) suggests that boosting the abundance of one of the body's own proteins might be more effective than antibiotic treatment at fighting off a common meningitis-causing bacterium (E. coli K1).

25 May 2010

British Columbia first in Canada to include Prevnar 13 in routine child immunization program

British Columbia is leading the way in vaccinations to protect children from serious disease. The province is the first in Canada to include Prevnar 13, the vaccine that provides the broadest coverage available against Streptococcus pneumoniae that may cause invasive pneumococcal disease, in the routine child immunization program.

21 May 2010

Kansas State University researcher awarded NIH grant to study antibiotic-resistant bacteria

Antibiotic-resistant bacteria are becoming a growing problem around the world, and are a particular worry in hospital-acquired infections.

20 May 2010

Vaccinations recommended for adults

Yearly vaccinations aren't just for kids any more. You probably heard a lot about a seasonal or H1N1 flu shot last fall, but you should know that a battery of other adult vaccinations might also become part of your health care routine. Pneumonia and shingles vaccines are preventive-care essentials for older adults, and meningitis and tetanus shots are now college rites of passage. Even the vaccines of childhood—measles, mumps and rubella, and whooping cough—are recommended for adults who missed out in their younger years.

19 May 2010

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

14 May 2010

Meningitis News and Research

Latest Meningitis News and Research

CREW calls for antitrust investigation into drug companies

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

AP reports on how newly approved meningitis vaccine could 'revolutionalize' prevention of disease in Africa

ESMT CA study: Cutting pharmaceutical prices will reduce number of new medications

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Health Canada recommends new pneumococcal vaccine for young children

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Scientist at Children Hospital Los Angeles receives NIH grant to research on meningitis

Researchers say ear tubes are safe for children with cochlear implants

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

BGS develops new bio filters for testing E. coli, salmonella, listeria and pseudomonas in food samples

Natural anti-inflammatory protein effective against meningitis-causing bacteria

British Columbia first in Canada to include Prevnar 13 in routine child immunization program

Kansas State University researcher awarded NIH grant to study antibiotic-resistant bacteria

Vaccinations recommended for adults

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Meningitis News and Research

Latest Meningitis News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in